Salute e Benessere
IGALMI Marks Significant Market Growth, Reaching New Heights in Treatment Accessibility | DelveInsight
IGALMI is the first newly approved acute treatment in over ten years for managing agitation linked to schizophrenia or bipolar disorder. It offers a unique approach to addressing this challenging and often distressing symptom. Agitation frequently occurs in individuals with bipolar I or II disorder or schizophrenia and can be difficult to control. Timely recognition and intervention are critical to prevent the symptom from escalating and leading to aggression. The FDA approved IGALMI based on findings from two key Phase III clinical trials—SERENITY I and SERENITY II—which were randomized, double-blind, placebo-controlled studies assessing its effectiveness in treating agitation in schizophrenia and bipolar disorder, respectively. IGALMI is administered sublingually or buccally. Patients should avoid chewing or swallowing the medication and must refrain from eating or drinking for at least 15 minutes after sublingual use or one hour after buccal use.
Apart from its FDA-approved use as IGALMI sublingual film, BXCL501 is an experimental, proprietary oral film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist. BioXcel Therapeutics is currently studying BXCL501 for potential use in treating acute agitation related to Alzheimer's dementia, as well as agitation linked to bipolar I or II disorder and schizophrenia in a home setting. These investigational uses have not yet been proven safe or effective. The FDA has granted BXCL501 Breakthrough Therapy designation for agitation associated with dementia and fast-track designation for treating agitation in schizophrenia, bipolar disorders, and dementia.
Learn more about IGALMI projected market sales @
Schizophrenia is a severe mental illness that impacts a person's thinking, emotions, decision-making abilities, and social functioning. It often begins in late adolescence or early adulthood in men and tends to appear later in women, typically in their late 20s to early 30s. Based on DelveInsight's analysis, there were diagnosed prevalent cases of schizophrenia across the 7MM in 2023, with the United States alone accounting for nearly cases.
The mainstay of treatment involves antipsychotic medications that act on dopamine pathways. Second-generation antipsychotics are generally favored due to their reduced risk of serious side effects. Long-acting injectable options can help improve patient adherence and overall outcomes. For individuals with severe or treatment-resistant forms of the disorder, high-dose medications may be necessary. In more critical situations, or when medications are ineffective, hospitalization or electroconvulsive therapy (ECT) may be required.
Several innovative treatments are expected to launch over the forecast period, leading to significant market growth. The schizophrenia market in the 7MM, valued at in 2023, is projected to expand substantially by 2034. This growth will be fueled by increasing awareness and a rising number of cases worldwide.
Discover more about the schizophrenia market in detail @
Several emerging therapies are expected to enter the schizophrenia market and pose strong competition to IGALMI. These include from Teva Pharmaceutical/MedinCell/Royalty Pharma, from Sunovion Pharmaceutical (Sumitomo Pharma)/Otsuka, from Reviva Pharmaceuticals, from Minerva Neurosciences/Mitsubishi Tanabe Pharma, from Rovi Pharmaceuticals Laboratories, from Neurocrine Biosciences/Mitsubishi Tanabe Pharma, from Lyndra Therapeutics, and from Newron Pharmaceuticals, among others.
To know more about the number of competing drugs in development, visit @
Discover how IGALMI is shaping the agitation associated with schizophrenia and bipolar disorder treatment landscape @
IGALMI is an oromucosal film formulation approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I and II disorders in adults. Market dynamics for IGALMI are influenced by its . Unlike traditional antipsychotics or benzodiazepines, IGALMI is a , offering a non-dopaminergic pathway for calming agitation without causing extrapyramidal symptoms or significant sedation, making it an attractive option for clinicians prioritizing patient safety and rapid control.
One of the key drivers of IGALMI's market potential is the and the in emergency rooms and inpatient psychiatric units. With agitation being a common symptom leading to hospitalization and often requiring immediate intervention, there is a that can be administered quickly and safely without the need for injections or IV access. IGALMI's sublingual film offers , particularly valuable in settings where patient cooperation may be limited.
However, IGALMI also faces market challenges. The often encounters resistance due to ingrained clinical practices, particularly the widespread use of intramuscular antipsychotics and benzodiazepines.
will also influence uptake, as IGALMI may be priced higher than generic alternatives. Additionally, some prescribers may remain cautious about alpha-2 agonist
, especially in medically complex patients.
Strategically, the success of IGALMI hinges on demonstrating reduced hospitalizations or restraints. could help establish its value proposition more clearly. If these hurdles are addressed successfully, IGALMI has the potential to redefine the standard of care for managing acute agitation in psychiatric populations.
Dive deeper to get more insight into IGALMI's strengths & weaknesses relative to competitors @
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key schizophrenia companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key schizophrenia companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bipolar depression companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key bipolar depression companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/igalmi-marks-significant-market-growth-reaching-new-heights-in-treatment-accessibility--delveinsight-302443755.html